Literature DB >> 32783111

A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy.

Sanjana Ballal1, Madhav Prasad Yadav1, Vasko Kramer2, Euy Sung Moon3, Frank Roesch3, Madhav Tripathi1, Soumyaranjan Mallick4, Sreedharan Thankarajan ArunRaj1, Chandrasekhar Bal5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32783111     DOI： 10.1007/s00259-020-04990-w

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  23 in total

1.  Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time.

Authors:  Euy Sung Moon; Sanjana Ballal; Madhav Prasad Yadav; Chandrasekhar Bal; Yentl Van Rymenant; Sarah Stephan; An Bracke; Pieter Van der Veken; Ingrid De Meester; Frank Roesch
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-12-15

2.  Dimeric FAPI with potential for tumor theranostics.

Authors:  Chunxia Qin; Yangmeihui Song; Weibo Cai; Xiaoli Lan
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-12-15

Review 3.  Novel Tracers and Radionuclides in PET Imaging.

Authors:  Christian Mason; Grayson R Gimblet; Suzanne E Lapi; Jason S Lewis
Journal:  Radiol Clin North Am       Date:  2021-09       Impact factor: 1.947

4.  Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of 68Ga-Labeled FAPI Dimer.

Authors:  Liang Zhao; Bo Niu; Jianyang Fang; Yizhen Pang; Siyang Li; Chengrong Xie; Long Sun; Xianzhong Zhang; Zhide Guo; Qin Lin; Haojun Chen
Journal:  J Nucl Med       Date:  2021-09-23       Impact factor: 11.082

5.  Enhanced antitumor immune responses via a new agent [131I]-labeled dual-target immunosuppressant.

Authors:  Chunjuan Jiang; Qiwei Tian; Xiaoping Xu; Panli Li; Simin He; Jian Chen; Bolin Yao; Jianping Zhang; Ziyi Yang; Shaoli Song
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-10-15       Impact factor: 10.057

6.  Diagnostic Value of 18F-NOTA-FAPI PET/CT in a Rat Model of Radiation-Induced Lung Damage.

Authors:  Xueting Qin; Shijie Wang; Xiaoli Liu; Jinghao Duan; Kai Cheng; Zhengshuai Mu; Jing Jia; Yuchun Wei; Shuanghu Yuan
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

7.  Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients.

Authors:  Justin Ferdinandus; Pedro Fragoso Costa; Lukas Kessler; Manuel Weber; Nader Hirmas; Karina Kostbade; Sebastian Bauer; Martin Schuler; Marit Ahrens; Hans-Ulrich Schildhaus; Christoph Rischpler; Hong Grafe; Jens T Siveke; Ken Herrmann; Wolfgang P Fendler; Rainer Hamacher
Journal:  J Nucl Med       Date:  2021-08-12       Impact factor: 11.082

8.  FAP-targeted radionuclide therapy with [177Lu]Lu-FAPI-46 in metastatic nasopharyngeal carcinoma.

Authors:  Kaili Fu; Yizhen Pang; Liang Zhao; Limei Lin; Hua Wu; Long Sun; Qin Lin; Haojun Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-12-08       Impact factor: 9.236

9.  68Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the 68Ga-FAPI PET Prospective Observational Trial.

Authors:  Lukas Kessler; Justin Ferdinandus; Nader Hirmas; Sebastian Bauer; Uta Dirksen; Fadi Zarrad; Michael Nader; Michal Chodyla; Aleksandar Milosevic; Lale Umutlu; Martin Schuler; Lars Erik Podleska; Hans-Ulrich Schildhaus; Wolfgang P Fendler; Rainer Hamacher
Journal:  J Nucl Med       Date:  2021-04-30       Impact factor: 11.082

10.  In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA5.SA.FAPi and DOTA.SA.FAPi.

Authors:  Euy Sung Moon; Yentl Van Rymenant; Sandeep Battan; Joni De Loose; An Bracke; Pieter Van der Veken; Ingrid De Meester; Frank Rösch
Journal:  Molecules       Date:  2021-06-08       Impact factor: 4.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.